Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00362102
Status:
COMPLETED
Last Update Posted:
2016-11-22
First Post:
2006-08-08
Brief Title:
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Organization Data
Organization:
Eli Lilly and Company
Class:
INDUSTRY
Study ID:
CA225-259
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Eli Lilly and Company
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None